Epizyme to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will participate in the following conferences in September:

• Citi’s 12th Annual Biotech Conference (panel discussion) on Wednesday, September 6, 2017 at 1:00 p.m. ET in Boston;
• Morgan Stanley’s 15th Annual Global Healthcare Conference (fireside chat) on Monday, September 11, 2017 at 4:15 p.m. ET in New York City;
• Cantor Fitzgerald’s 3rd Annual Healthcare Conference (presentation) on Tuesday, September 26, 2017 at 3:25 p.m. ET in New York City; and,
• Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology (fireside chat) on Wednesday, September 27, 2017 at 8:30 a.m. ET in New York City.

Replays of the webcasts will be available in the investor section of the company’s website at http://www.epizyme.com for 60 days following the call and presentation.

About Epizyme, Inc. Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting cancer treatment through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy and in relapsed and front-line disease. Using the Company's proprietary platform, Epizyme has pioneered the identification and development of small molecule inhibitors of chromatin modifying proteins (CMPs), such as tazemetostat. CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, which can allow cancer cells to grow and proliferate. By focusing on the genetic drivers of cancers, Epizyme's science seeks to match targeted medicines with the specific patients that need it. For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx. 

Contacts:
Cheya Pope, Epizyme, Inc.
[email protected]
617-229-7561

Monique Allaire, THRUST IR
[email protected]
(617) 895-9511

You May Also Be Interested In

• Humaans Expands Into US Payroll As It Accelerates US Growth
• Bio Ionic Partners with Ulta Beauty on Limited Edition Jade Dream Collection
• Best Crypto to Buy Now Is Not ETH or SOL and Pepeto Proves Why Before